TRANSFORM™Multi-CenTer Experience With the Rapid Deployment EDWARDS INTUITY Valve System FOR Aortic Valve ReplaceMent
EDWARDS INTUITY valve
Maladie de la valve aortique+4
+ Maladies Cardiovasculaires
+ Maladies Cardiaques
Étude thérapeutique
Résumé
Date de début de l'étude : 26 septembre 2012
Date à laquelle le premier participant a commencé l'étude.This is a prospective, non-randomized, multi-center trial. Up to 950 subjects will be enrolled at up to 35 centers in the US. After replacement of their aortic heart valve with the EDWARDS INTUITY valve system, each patient will have routine follow-up tests at the following intervals: discharge, 3 months, 1 year, and annually thereafter for a minimum of five years.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.934 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.À partir de 18 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Inclusion Criteria: Inclusion Criteria - Subjects will be required to meet all inclusion criteria: Male or female, age 18 years or older Has aortic stenosis or stenosis-insufficiency of an aortic valve requiring a planned replacement as indicated in the preoperative evaluation Is scheduled to undergo planned aortic valve replacement with or without concomitant coronary bypass surgery Provide written informed consent Geographically stable and agrees to attend follow-up assessments until all subjects have completed 5 years of follow up Exclusion Criteria: - Exclusion Criteria - Subjects will not be eligible for trial participation if any of the following criteria are present: Pure aortic insufficiency Requires emergency surgery Previous aortic valve replacement Had prior mitral, tricuspid or pulmonic valve surgery, which included implant of a bioprosthetic valve, mechanical valve, or annuloplasty ring that will remain in situ Requires multiple valve replacement/repair Requires a surgical procedure outside of the cardiac area (e.g., vascular endarterectomy, vascular bypass, tumor removal) Aneurysm of the aortic root and/or ascending aorta requiring surgical intervention Active endocarditis/myocarditis or endocarditis/ myocarditis within 3 months prior to the scheduled AVR surgery Myocardial infarction (MI) within thirty (30) days prior to valve replacement surgery Renal insufficiency as determined by creatinine ≥ 2.5 mg/dL at screening or end-stage renal disease requiring chronic dialysis Hyperparathyroidism MRI or CT-scan confirmed cerebrovascular accident (CVA), or transient ischemic attack (TIA) within 6 months (180 days) of the procedure Presence of non-cardiac disease limiting life expectancy to less than 12 months Hypertrophic obstructive cardiomyopathy (HOCM) Left ventricular ejection fraction ≤ 25% Documented history of substance (drug or alcohol) abuse within the last 5 years Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation Hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to the procedure Pregnancy, lactation, or planning to become pregnant; Currently incarcerated or unable to give voluntary informed consent Leucopenia (WBC < 3.5x 103/µL), or acute anemia (Hgb < 10.0 gm/dL or 6 mmol/L), or thrombocytopenia (platelet count < 50x 103/µL), or history of bleeding diathesis or coagulopathy History of myxomatous disease/connective tissue disorders (e.g., Marfan's Syndrome) Current or recent participation (within 6 weeks prior to surgery) in an investigational drug or device trial Intra-operative Exclusion Criteria Anatomic variances which contraindicate implant of the trial valve, such as: anomalous coronary arteries annular deformation or extensive calcification of the annulus or aortic root which cannot be removed significant calcium on the anterior mitral leaflet pronounced septal calcification position of coronary ostia relative to Model 8300ACD valve that would result in obstruction of blood flow Available devices are not suitably sized for the subject's annulus
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.Un seul groupe d'intervention est désigné dans cette étude
Cette étude ne comporte pas de groupe placebo.
Groupes de traitement
Groupe I
ExpérimentalObjectifs de l'étude
Objectifs principaux
Objectifs secondaires
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 29 sites
Keck Hospital of University of Southern California
Los Angeles, United StatesOuvrir Keck Hospital of University of Southern California dans Google MapsUniversity of California Los Angeles
Los Angeles, United StatesHoag Memorial Hospital Presbyterian
Newport Beach, United StatesStanford University
Palo Alto, United States